Judith A Potashkin

List of Publications by Year
in descending order

52 papers	2,571 citations	201674 27 h-index	197818 49 g-index
53 all docs	53 docs citations	53 times ranked	3919 citing authors

#	Article	IF	Citations
1	A Potential Role for U2AF-SAP 155 Interactions in Recruiting U2 snRNP to the Branch Site. Molecular and Cellular Biology, 1998, 18, 4752-4760.	2.3	247
2	Shared dysregulated pathways lead to Parkinson's disease and diabetes. Trends in Molecular Medicine, 2013, 19, 176-186.	6.7	183
3	Modeling PD pathogenesis in mice: Advantages of a chronic MPTP protocol. Parkinsonism and Related Disorders, 2008, 14, S112-S115.	2.2	163
4	The emerging role of nutrition in Parkinson's disease. Frontiers in Aging Neuroscience, 2014, 6, 36.	3.4	161
5	Finding useful biomarkers for Parkinsonâ€™s disease. Science Translational Medicine, 2018, 10, .	12.4	125
6	MicroRNAs miR-186 and miR-150 Down-regulate Expression of the Pro-apoptotic Purinergic P2X7 Receptor by Activation of Instability Sites at the 3â€²-Untranslated Region of the Gene That Decrease Steady-state Levels of the Transcript. Journal of Biological Chemistry, 2008, 283, 28274-28286.	3.4	122
7	The Impact of Disease Comorbidities in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 631770.	3.4	105
8	Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinsonâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2257-2262.	7.1	96
9	The Promise of Neuroprotective Agents in Parkinson?s Disease. Frontiers in Neurology, 2011, 2, 68.	2.4	94
10	System-based approaches to decode the molecular links in Parkinson's disease and diabetes. Neurobiology of Disease, 2014, 72, 84-91.	4.4	87
11	A network approach to clinical intervention in neurodegenerative diseases. Trends in Molecular Medicine, 2014, 20, 694-703.	6.7	76
12	Integrative Network Analysis Unveils Convergent Molecular Pathways in Parkinson's Disease and Diabetes. PLoS ONE, 2013, 8, e83940.	2.5	73
13	Dissecting the Molecular Mechanisms of Neurodegenerative Diseases through Network Biology. Frontiers in Aging Neuroscience, 2017, 9, 166.	3.4	73
14	Regulation of fosB and Î”fosB mRNA expression: In vivo and in vitro studies. Brain Research, 2007, 1143, 22-33.	2.2	67
15	Biological and Clinical Implications of Comorbidities in Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2017, 9, 394.	3.4	67
16	The Role of Oxidative Stress in the Dysregulation of Gene Expression and Protein Metabolism in Neurodegenerative Disease. Antioxidants and Redox Signaling, 2006, 8, 144-151.	5.4	59
17	Biosignatures for Parkinsonâ€™s Disease and Atypical Parkinsonian Disorders Patients. PLoS ONE, 2012, 7, e43595.	2.5	52
18	Cell-division-cycle defects associated with fission yeast pre-mRNA splicing mutants. Current Genetics, 1998, 34, 153-163.	1.7	51

#	Article	IF	Citations
19	Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program. Biomarkers in Medicine, 2017, 11, 451-473.	1.4	49
20	Integrative transcriptomic meta-analysis of Parkinsonâ€™s disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinsonâ€™s disease. Scientific Reports, 2016, 6, 34579.	3.3	41
21	Splicing of the U6 RNA precursor is impaired in fission yeast pre-mRNA splicing mutants. Nucleic Acids Research, 1989, 17, 7821-7831.	14.5	37
22	Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinsonâ€™s Disease Patients. PLoS ONE, 2015, 10, e0142582.	2.5	37
23	Decreased expression of P2X7 in endometrial epithelial pre-cancerous and cancer cells. Gynecologic Oncology, 2007, 106, 233-243.	1.4	35
24	SchizosaccharomycesU6 genes have a sequence within their introns that matches the B box consensus of tRNA internal promoters. Nucleic Acids Research, 1990, 18, 2025-2032.	14.5	33
25	Transcriptomic and Network Analysis Highlight the Association of Diabetes at Different Stages of Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2019, 13, 1273.	2.8	33
26	Blood Transcriptomic Meta-analysis Identifies Dysregulation of Hemoglobin and Iron Metabolism in Parkinsonâ€™ Disease. Frontiers in Aging Neuroscience, 2017, 9, 73.	3.4	31
27	Network Analysis Identifies SOD2 mRNA as a Potential Biomarker for Parkinson's Disease. PLoS ONE, 2014, 9, e109042.	2.5	30
28	Meta-Analysis of Gene Expression Changes in the Blood of Patients with Mild Cognitive Impairment and Alzheimerâ€™s Disease Dementia. International Journal of Molecular Sciences, 2019, 20, 5403.	4.1	29
29	Regulation of Retention of FosB Intron 4 by PTB. PLoS ONE, 2007, 2, e828.	2.5	24
30	Isolation and initial characterization of residual nuclear structures from yeast. Experimental Cell Research, 1984, 153, 374-388.	2.6	23
31	Computational identification of key genes that may regulate gene expression reprogramming in Alzheimerâ€™s patients. PLoS ONE, 2019, 14, e0222921.	2.5	22
32	Specific splice variants are associated with Parkinson's disease. Movement Disorders, 2013, 28, 1724-1727.	3.9	20
33	Characterization of DNA sequences associated with residual nuclei of Saccharomyces cerevisiae. Experimental Cell Research, 1986, 165, 29-40.	2.6	18
34	MPTP administration in mice changes the ratio of splice isoforms of fosB and rgs9. Brain Research, 2007, 1182, 1-10.	2.2	18
35	A network approach to diagnostic biomarkers in progressive supranuclear palsy. Movement Disorders, 2014, 29, 550-555.	3.9	17
36	Evaluation of RNA Blood Biomarkers in the Parkinsonâ€™s Disease Biomarkers Program. Frontiers in Aging Neuroscience, 2018, 10, 157.	3.4	17

#	Article	IF	Citations
37	Transcriptomic and Network Analysis Identifies Shared and Unique Pathways across Dementia Spectrum Disorders. International Journal of Molecular Sciences, 2020, 21, 2050.	4.1	17
38	Key Disease Mechanisms Linked to Alzheimerâ€™s Disease in the Entorhinal Cortex. International Journal of Molecular Sciences, 2021, 22, 3915.	4.1	17
39	Evaluation of RNA Blood Biomarkers in Individuals at Risk of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2017, 7, 653-660.	2.8	15
40	Physical Activity Rewires the Human Brain against Neurodegeneration. International Journal of Molecular Sciences, 2022, 23, 6223.	4.1	15
41	A Comparison of Gene Expression Changes in the Blood of Individuals Consuming Diets Supplemented with Olives, Nuts or Long-Chain Omega-3 Fatty Acids. Nutrients, 2020, 12, 3765.	4.1	12
42	Bioinformatic Analysis Reveals Phosphodiesterase 4D-Interacting Protein as a Key Frontal Cortex Dementia Switch Gene. International Journal of Molecular Sciences, 2020, 21, 3787.	4.1	12
43	Network Analysis Identifies Sex-Specific Gene Expression Changes in Blood of Amyotrophic Lateral Sclerosis Patients. International Journal of Molecular Sciences, 2021, 22, 7150.	4.1	12
44	Mutations in the large subunit of U2AF disrupt pre-mRNA splicing, cell cycle progression and nuclear structure. Yeast, 2000, 16, 1001-1013.	1.7	11
45	Current Challenges Towards the Development of a Blood Test for Parkinsonâ€™s Disease. Diagnostics, 2014, 4, 153-164.	2.6	10
46	PTPRC Expression in Blood is Downregulated in Parkinsonâ€™s and Progressive Supranuclear Palsy Disorders. Journal of Parkinson's Disease, 2018, 8, 529-537.	2.8	10
47	Transcriptomic and Network Meta-Analysis of Frontotemporal Dementias. Frontiers in Molecular Neuroscience, 2021, 14, 747798.	2.9	8
48	BTF3 is evolutionarily conserved in fission yeast. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1996, 1308, 182-184.	2.4	7
49	Key Disease Mechanisms Linked to Amyotrophic Lateral Sclerosis in Spinal Cord Motor Neurons. Frontiers in Molecular Neuroscience, 2022, 15, 825031.	2.9	7
50	Reply to Liu et al.: HNF4A and PTBP1 expression in the brain of neurodegenerative disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3976.	7.1	1
51	Reply to Toker and Pavlidis: Blood biomarkers for Parkinsonâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3638-E3638.	7.1	0
52	Blood biomarkers associated with cognitive decline in early stage and drug-naive Parkinson's disease patients. Parkinsonism and Related Disorders, 2016, 22, e60.	2.2	0